Update on the current use of hormonals as therapy in advanced breast cancer

Anti-Cancer Drugs

Volumn 14, Issue 4, 2003, Pages 265-273

  Vogel, Charles L ^a,b  

^a Cancer Research Network   (United States)

^b NONE   (United States)

Author keywords

Antiaromatase agents; Breast cancer; Exemestane; Hormonal therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; HYDROCORTISONE; LETROZOLE; MEGESTROL ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ENDOMETRIAL DISEASE; HUMAN; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; VAGINA BLEEDING;

AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGEN ANTAGONISTS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; TAMOXIFEN; TOREMIFENE;

EID: 0038243777     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200304000-00003     Document Type: Review

References (69)

1. Blankenstein MA, van de Ven J, Maitimu-Smeele I, et al. Intratumoral levels of estrogens in breast cancer. J Steroid Biochem Mol Biol 1999; 69:293-297.
2. Elledge RM, Fuqua SAW. Estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (editors): Diseases of the Breast, 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2000, p. 471.
3. Osborne CK, Hamilton B, Titus G, et al. Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res 1980; 40:2361-2366.
4. Allegra JC, Lippman AE. Estrogen receptor status and the disease-free interval in breast cancer. Recent Res Cancer Res 1980; 71:20-25.
5. DeSombre E, Green G, Jensen E. Estrophillin and endocrine responsiveness of breast cancer. In: McGuire W (editor): Hormones, Receptors and Breast Cancer. New York: Raven Press; 1978, p. 1.
6. Paridaens R, Sylvester RJ, Ferrazzi E, et al. Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 1980; 46:2889-2895.
7. Edwards DP, Chamness GC, McGuire WL. Estrogen and progesterone receptor proteins in breast cancer. Biochim Biophys Acta 1979; 560:457-486.
8. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985; 48:2900-2906.
9. Bajetta E, Celio L, Buzzoni R, Bichisao E. Novel non-steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer? Tumori 1996; 82:417-422.
10. Njar VC, Brodie AM. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 1999; 58:233-255.
11. Lonning PE. Clinico-pharmacological aspects of different hormone treatments. Eur J Cancer 2000; 36 (suppl 4):81-82.
12. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999; 6:75-92.
13. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:71-85.
14. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer:an overview of the randomised trials. Lancet 1998; 381:1451-1467.
15. Vogel VG. Breast cancer prevention: a review of current evidence. CA Cancer J Clin 2000; 50:156-170.
16. Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer. Eur J Cancer 1996; 32A:576-588.
17. Holliday SM, Faulds D. Management of advanced breast cancer: defining the role of toremifene. Dis Manage Health Outcomes 1998; 3:143-152.
18. Vogel CL, East DR, Wang G, Voigt W, Thomsen S. Response to Nolvadex in estrogen receptor 'poor' metastatic breast cancer. Cancer 1987; 60:1184-1189.
19. Pyrhonen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. Br J Cancer 1997; 76:270-277.
20. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 1997; 45:251-262.
21. Wiseman LR, Goa KL. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs 1997; 54:141-160.
22. Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13:2556-2566.
23. Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge Jr GW. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 2000; 88:2047-2053.
24. Clemett D, Spencer CM. Raloxifene. A review of its use in postmenopausal osteoporosis. Drugs 2000; 60:379-411.
25. Jubelirer SJ, Crowell EB Jr. The STAR (study of tamoxifen and raloxifene) trial in West Virginia. WV Med J 2000; 96:602-604.
26. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer 2000; 89:817-25.
27. Howell A, Osborne CK, Robertson JFR, Jones SE, Mauriac L. ICI 182780 (Faslodex) versus anastrezele (Arimidex) for the treatment of advanced breast cancer in postmenopausal women - prospective combined analysis of two multicenter trials. Eur J Cancer 2001; 37:151.
28. Buzdar AU. Role of aromatase inhibitors in advanced breast cancer. Endocr Relat Cancer 1999; 6:219-225.
29. di Salle E, Ornati G, Giudici D, Lassus M, Evans TR, Coombes RC. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1992; 43:137-143.
30. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 1988; 30:391-394.
31. Crucitta E, Lorusso V, Attolico M, Sambiasi D, Mazzei A, De Lena M. New aromatase inhibitors in the treatment of advanced breast cancer. Int J Oncol 2000; 17:1037-1041.
32. Smith IE, Harris AL, Morgan M, et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed) 1981; 283:1432-1434.
33. Lipton A, Harvey HA, Santen RJ, et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982; 42:3434s-3436s.
34. Alense-Munez MC, Ojeda-Genzalez MB, Beltran-Fabergat M, et al. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced breast cancer. Oncology 1988; 44:350-353.
35. Gale KE, Andersen JW, Tormey DC, et al. Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer 1994; 73:354-361.
36. Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 1999; 6:187-195.
37. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998; 83:1142-1152.
38. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral arematase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453-461.
39. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole and aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19:3357-3366.
40. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer:results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18:1399-1411.
41. Messori A, Cattel F, Trippoli S, Vaiani M. Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. Anticancer Drugs 2000; 11:701-716.
42. Perez Carrion R, Alberola Candel V, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994; 5:S19-S24.
43. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18:3748-3757.
44. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18:3758-3767.
45. Robertson J, Buzdar A, Nabholtz J, et al. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women - prospective combined analysis from two international trials. Eur J Cancer 2000; 36:S88.
46. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596-2606.
47. Paridaens R, Dirix LY, Beex L, et al. Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): results of a randomized phase II trial. Proc Am Soc Clin Oncol 2000; 19:103a.
48. Dirix L, Piccart MJ, Lohrisch C, et al. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment on Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 2001; 21:29a.
49. Lonning PE. Pharmacology and clinical experience with exemestane. Expert Opin Invest Drugs 2000; 9:1897-1905.
50. Dixon JM, Love CDB, Tucker S, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Proc Am Soc Clin Oncol 1998; 17:104a.
51. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12:1527-1532.
52. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3808-3816.
53. Pritchard K, Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: will it play in Peoria? J Clin Oncol 2001; 19:3795-3797.
54. Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000; 6:2229-2235.
55. Dixon JM, Anderson T, Miller WR. Phase IIb study of neoadjuvant exemestane (EXE) in locally advanced breast cancer. Proc Am Soc Clin Oncol 2001; 20:406 (abstr 1908).
56. Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 2002; 21:34a.
57. The ATAC Trialists' Group. Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months of exposure data: a safety update from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. Proc San Antonio Breast Cancer Symp 2002; 76 (Suppl 1): S-56 (abstr 633).
58. Milla-Santos A, Milla L, Portella J, et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer-updated efficacy results based on a median follow-up of 47 months. Proc San Antonio Breast Cancer Symp 2002; 76 (Suppl 1):S-32 (abstr 13).
59. Goss PE, Grynpas MD, Qi S, Hu H. The effects of exemestane on bone and lipids in the ovariectomized rat. Breast Cancer Res Treat 2001; 69:224.
60. Harper-Wynne C, Ross G, Sacks N, Gui G, Dowsett M. Effects of the aromatase inhibitor letrozole in healthy postmenopausal women: rationale for prevention. Proc Am Soc Clin Oncol 2001; 20:3356 (abstr 3091).
61. Jones S, Vogel C, Arkhipov A et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 1999; 17:3418-3425.
62. Jones S, Chang A, Lusch C, et al. A phase II confirmatory study of antitumor efficacy and safety of exemestane (EXE) as third-line hormonal treatment of postmenopausal patients (PTS) with metastatic breast cancer (MBC) refractory to tamoxifen (Tam) and Megestrol acetate. Proc San Antonio Breast Cancer Symp 2 1998; 50:305 (abstr 437).
63. Jones S, Belt R, Cooper B, et al. A phase II study of antitumor efficacy and safety of exemestane (EXE) as second-line hormonal treatment of postmenopausal patients with metastatic breast cancer (MBC) refractory to tamoxifen (Tam). Proc San Antonio Breast Cancer Symp 2 1998; 50:304 (abstr 436).
64. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. Results Of a double-blind randomised phase III trial. Eur J Cancer 2000; 36 (suppl 4):S86-S87.
65. Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000; 36:976-982.
66. Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18:2234-2244.
67. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997; 79:730-739.
68. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32A:404-412.
69. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg, daily 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998; 9:639-645.